DVA.V - Delivra Corp.

TSXV - TSXV Delayed Price. Currency in CAD
0.3400
-0.0300 (-8.11%)
As of 10:18AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.3700
Open0.3450
Bid0.3400 x 0
Ask0.3650 x 0
Day's Range0.3400 - 0.3450
52 Week Range0.2300 - 0.6100
Volume15,000
Avg. Volume39,495
Market Cap16.156M
Beta (3Y Monthly)3.30
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • CNW Group25 days ago

    Delivra Announces Q1 2019 Results

    TORONTO, May 30, 2019 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") reported its financial results for the three months ended March 31, 2019. Delivra's financial statements are prepared in accordance with International Financial Reporting Standards. Announced on March 4, 2019, that Delivra entered into a definitive arrangement agreement with Harvest One Cannabis Inc. ("Harvest One"), pursuant to which Harvest One will acquire all of the issued and outstanding common shares of Delivra.

  • Delivra Corp. Announces Shareholder Approval of Plan of Arrangement
    CNW Group28 days ago

    Delivra Corp. Announces Shareholder Approval of Plan of Arrangement

    TORONTO, May 28, 2019 /CNW/ - A special meeting (the "Special Meeting") of the holders (the "Shareholders") of common shares (the "Shares") in the capital of Delivra Corp. (the "Corporation" or "Delivra") was held on Friday, May 24, 2019 at 10:00am at the Best Western Premier C Hotel located at 1530 Stone Church Road East, Hamilton, Ontario, Canada. A total of 26,642,787 Shares, representing 56.07% of the Corporation's 47,517,020 issued and outstanding Shares as at the record date for the Special Meeting, were represented in person or by proxy at the Special Meeting.

  • CNW Group2 months ago

    Delivra Announces Record Sales For 2018

    TORONTO, April 11, 2019 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") reported its financial results for the three and twelve months ended December 31, 2018. Delivra's financial statements are prepared in accordance with International Financial Reporting Standards.

  • CNW Group3 months ago

    States Attract New Wave of Tourism With Legalized Cannabis

    NEW YORK, March 18, 2019 /CNW/ --Last year, Canada became the second country ever to legalize cannabis entirely, joining Uruguay as the world pacesetters. Now, visitors across the world are flocking to the nation to try legal cannabis. Currently, the U.S. has only 10 states and the District of Columbia that have legalized cannabis entirely and states such as California, Colorado, and Nevada are the biggest market drivers.

  • ABN Newswire4 months ago

    MMJ Group Holdings Ltd (ASX:MMJ) Portfolio Update

    Perth, Australia, Mar 5, 2019 - (ABN Newswire) - MMJ Group Holdings Limited (ASX:MMJ) (OTCMKTS:MMJJF) ("MMJ") provides an update on recent events in the MMJ investment portfolio. 1. Portfolio ...

  • CNW Group4 months ago

    IIROC Trading Resumption - DVA

    VANCOUVER , March 4, 2019 /CNW/ - Trading resumes in: Company: Delivra Corp. TSX-Venture Symbol: DVA (all issues) Resumption (ET): 9:30 AM IIROC can make a decision to impose a temporary suspension (halt) ...

  • Harvest One Acquires Delivra to Strengthen its Medical and Wellness Division
    CNW Group4 months ago

    Harvest One Acquires Delivra to Strengthen its Medical and Wellness Division

    TORONTO, March 4, 2019 /CNW/ - Harvest One Cannabis Inc. (TSXV: HVT, OTCQX: HRVOF – "Harvest One") and Delivra Corp. (TSXV: DVA – "Delivra") are pleased to announce today that they have entered into a definitive arrangement agreement (the "Arrangement Agreement") pursuant to which Harvest One will acquire all of the issued and outstanding common shares of Delivra (the "Delivra Shares") (the "Transaction"). Under the terms of the Arrangement Agreement, shareholders of Delivra ("Delivra Shareholders") will receive 0.595 common shares of Harvest One (the "Harvest One Shares") for each Delivra Share (the "Exchange Ratio"). Harvest One, an international cannabis house of brands in the self-care and health and wellness space, has acquired Delivra as a means to further its strategy of providing trusted, effective products to help people in their daily lives.

  • CNW Group4 months ago

    IIROC Trading Halt - DVA

    VANCOUVER , March 4, 2019 /CNW/ - The following issues have been halted by IIROC: Company: Delivra Corp. TSX-Venture Symbol: DVA (all issues) Reason: At the Request of the Company Pending News Halt Time ...

  • CNW Group5 months ago

    Delivra Publishes Positive Results Utilizing its Unique Platform Technology for Topical Doxycycline

    TORONTO, Feb. 6, 2019 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") today announced the publication of positive data from a laboratory and clinical study demonstrating the stability, safety and efficacy to treat diabetic wounds, using Delivra's platform technology, to deliver a topical version of the prescription drug, doxycycline. "This impressive data further validates Delivra's novel technology and offers doctors and their patients an effective, safe and convenient cream for diabetic wounds, without the side effects of oral doxycycline. Delivra has filed a provisional patent to protect its unique formulation using doxycycline.

  • ACCESSWIRE5 months ago

    Today's Research Reports on Oncolytics Biotech, Delivra, Aptose Biosciences and ProMIS Neurosciences

    NEW YORK, NY / ACCESSWIRE / January 28, 2019 / The Market Wealth Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Group6 months ago

    Delivra publishes positive results utilizing its novel platform technology for Varicose Veins

    TORONTO, Jan. 8, 2019 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") today announced the publication of positive data from a clinical study demonstrating the safety and efficacy to treat chronic venous insufficiency of lower limbs, using the LivReliefTM Varicose Vein Cream over-the-counter product. In a human clinical setting, undertaken by an independent third-party medical clinic, LivReliefTM Varicose Vein Cream provided significant therapeutic improvement in the treated lower limbs after six weeks of treatment. In the study, LivReliefTM Varicose Vein Cream was tested in humans with severe lower limb pain.

  • ACCESSWIRE6 months ago

    Today's Research Reports on Delivra, Copper Mountain Mining, Ballard Power Systems and Pattern Energy

    NEW YORK, NY / ACCESSWIRE / December 14, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • CNW Group6 months ago

    Delivra publishes positive results using its platform technology for topical Advil™ (ibuprofen) and Celebrex™ (celecoxib)

    TORONTO, Dec. 11, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") today announced the publication of positive data from a pre-clinical study demonstrating the safety and efficacy to treat pain directly with a topical version of Advil™ (ibuprofen) and Celebrex™ (celecoxib). In pre-clinical testing, undertaken by an independent third-party research organization, the Delivra-ibuprofen and Delivra-celecoxib formulations provided sustained pain reduction. In the study, both Delivra formulations were tested in an acute dog model of arthritis where the formulation performed equally or better for swelling and pain reduction compared its oral equivalent and test controls.

  • CNW Group7 months ago

    View from the C-Suite: Dr. Joseph Gabriele, Chief Executive Officer, Delivra Corp., tells his company's story. Filmed on November 27, 2018

    TORONTO , Nov. 27, 2018 /CNW/ -   https://www.youtube.com/watch?v=xIkuz0mNwPY The View from the C-Suite video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange ...

  • CNW Group7 months ago

    Delivra Achieves Record Third Quarter 2018 Revenues

    TORONTO, Nov. 19, 2018  /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") reported its financial results for the three and nine months ended September 30, 2018. Delivra's financial statements are prepared in accordance with International Financial Reporting Standards.

  • CNW Group8 months ago

    Ernst & Young Names Dr. Joseph Gabriele of Delivra - Entrepreneur of the Year 2018 Ontario Award in the Health Care Category

    TORONTO, Oct. 30, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company"), a science and biotechnology company, today announced that its Founder and CEO, Dr. Joseph Gabriele, is the recipient of the Ernst & Young Entrepreneur Of The Year 2018 Ontario award in the Health Care category. "I'm humbled and honoured by the award", said Joseph Gabriele.

  • CNW Group8 months ago

    Delivra Announces Stock Option Grant and Postponement of Warrant Expiry

    TORONTO, Oct. 15, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company"), a scientific and biotechnology company, today announced that it has issued an aggregate of 550,000 incentive stock options (the "Options") each exercisable into one common share in the capital of the Company, to eligible participants under the Company's incentive stock option plan (the "Plan"). The Company also makes reference to the 700,000 share purchase warrants, exerciseable between $0.60 and $0.61 per share, expiring on October 31, 2018. Pursuant to the terms of the warrants, the warrant expiry date has been postponed until the third business day following the lifting of the "blackout period" that will be in effect on October 31, 2018 in connection with the release of the Company's September 30th, 2018 financial results.

  • CNW Group9 months ago

    Delivra Receiving Interest for its Expertise and Technology for Use in the Cannabis and Pharma Industries

    TORONTO, Oct. 1, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company"), a scientific and biotechnology company, today announced that it has recently received inquiries from a number of interested parties in relation to the Company's proprietary transdermal delivery system platform, including its proprietary applications for the cannabis and pharma industries. As a result of these inquiries, the Company has engaged Canaccord Genuity Corp. to act as exclusive financial advisor to identify, review, analyze and explore the range of strategic and other opportunities available to the Company within the cannabis and pharma industries. There can be no assurance that the Company will enter into any transaction, that there will be any change in the operation or ownership of the Company, or that the Company will take any other corporate action as a result of the review.

  • CNW Group10 months ago

    Delivra announces appointment of Chief Financial Officer

    TORONTO, Aug. 27, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") today announces the appointment of Pascal Attard as the Company's Chief Financial Officer. Mr. Attard has been with the Company since June 2015. For the past two years, Mr. Attard served as the Company's Vice-President, Finance and prior to that, was the Company's Controller.

  • CNW Group10 months ago

    Delivra achieves record second quarter 2018 results

    TORONTO, Aug. 20, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") reported its financial results for the three and six months ended June 30, 2018. Delivra's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").